Search

Young women with breast cancer who receive neoadjuvant chemotherapy are more likely to decline referral to reproductive endocrinology and infertility specialists than women who receive adjuvant chemotherapy.

… Tuesday, September 8, 2020 Young women with breast cancer who receive neoadjuvant chemotherapy (NAC) are more likely to decline referral to reproductive endocrinology and infertility (REI) specialists than women who receive adjuvant chemotherapy, according to our retrospective study published recently

Radiation therapy after surgery can sharply reduce the chance that certain low-risk breast cancers will return.

… Sunday, October 21, 2018 Summary Ductal carcinoma in situ (DCIS) is a low-risk form of early-stage breast cancer . Women with DCIS can have radiation after the tumor is removed to lower the risk that the cancer could come back. A new study provides more evidence that radiation after surgery can greatly

Learn more about the work of MSK lymphoma researchers being presented at the 2019 meeting of the American Society of Hematology.

… Sunday, December 8, 2019 Summary MSK researchers report advances in the treatment of various types of lymphoma at the annual meeting of the American Society of Hematology. The American Society of Hematology (ASH) annual meeting is the world’s premier event devoted to the study of blood cancers and disorders

Meet Hillary Esposito, who served in the US Military and is now an administrative assistant in Memorial Sloan Kettering Cancer Center's Department of Medicine.

… Thursday, November 11, 2021 Hillary Esposito lives to challenge herself. “Most people don’t challenge themselves enough,” she says. “I’ve always been adventurous and love the feeling and excitement of taking on something new and knowing that I’m growing as a leader.” Ms. Esposito joined Memorial Sloan

The experimental “smart-bomb” drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer, according to results from a first-in-human clinical trial to be presented today by a MSK researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

… Sunday, June 5, 2016 The experimental “smart-bomb” drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer

The study represents 20 years of research at MSK.

… Wednesday, January 31, 2018 Summary For adults with relapsed leukemia, CAR T cell therapy  is a potentially lifesaving treatment option. A clinical trial conducted at Memorial Sloan Kettering shows the long-term benefit of the approach and suggests ways to make it safer and more effective. Results published

Sun Hur of Harvard Medical School and Boston Children’s Hospital was one of the recipients of the 2021 Paul Marks Prize for Cancer Research.

… Thursday, March 10, 2022 The Paul Marks Prize for Cancer Research was created by the Boards of Memorial Sloan Kettering Cancer Center to honor the late Paul Marks , who served as President and CEO of MSK for almost 20 years, beginning in 1980. Awarded every other year since 2001, the prize recognizes

Researchers find a potential new route to making immunotherapy work better in pancreatic cancers and possibly others.

… Wednesday, February 19, 2020 Summary Current immunotherapies don’t work for most people with cancer. Researchers have identified an overlooked immune cell type that may react to targeted therapies to rally a more powerful immune response in more cancer patients. Immunotherapy is showing great promise

Learn about the eight students who successfully defended their dissertations and will be awarded PhD degrees during the Gerstner Sloan Kettering Graduate School of Biomedical Sciences commencement ceremony on May 27.

… Friday, May 22, 2020 Summary Next week, eight students will receive PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). James Allison, a 2018 Nobel laureate and chair of the department of immunology at MD Anderson Cancer Center, will be the featured speaker at

A multi-institutional effort led by MSK’s Charles Sawyers is seeking to interpret information about the genetic causes of cancer.

… Tuesday, January 5, 2016 Summary Advances in gene sequencing methods have revolutionized our genetic understanding of cancer. But they’ve also led to such large quantities of data that scientists are struggling to analyze it all. Now a multicenter project aims to find better ways to interpret this abundance